. Author manuscript; available in PMC: 2013 Jun 17.

Published in final edited form as: Chem Soc Rev. 2012 Mar 5;41(7):2971–3010. doi: 10.1039/c2cs15344k

Table 1.

Targeted NPs in clinical development

Identity	Ligand	Target	Nanoparticle	Active Pharmaceutical Ingredient (API)	Indication	Status	Reference
BIND-014	Small molecule	PSMA^a	Polymeric	Docetaxel	Solid tumours	Phase I	19
SEL-068	Small molecule	Antigen presenting cells	Polymeric	Nicotine antigen T-helper cell peptide, TLR^b agonist	Smoking cessation and relapse prevention vaccine	Phase I	20
CALAA-01	Transferrin	Transferrin receptor	Polymeric	siRNA	Solid tumours	Phase I	28
MBP-426	Transferrin	Transferrin receptor	Liposome	Oxaliplatin	Gastric, esophageal, gastroesophageal adenocarcinoma	Phase Ib/II	29
MCC-465	Antibody fragment	Tumour antigen	Liposome	Doxorubicin	Metastatic stomach cancer	Phase I	30
SGT53-01	Antibody fragment	Transferrin receptor	Liposome	p53 gene	Solid tumours	Phase Ib	31

PSMA: prostate specific membrane antigen.

TLR: Toll-Like Receptor agonist.